成人ヘモグロビン血症検査市場：グループ、タイプ、エンドユーザー別-2025-2030年の世界予測

成人ヘモグロビン血症検査市場は、2023年に47億2,000万米ドルと評価され、2024年には51億米ドルに達すると予測され、CAGR 6.17％で成長し、2030年には71億8,000万米ドルに達すると予測されています。

成人ヘモグロビン血症検査は、成人における鎌状赤血球症やβサラセミアなどのヘモグロビン産生異常を特徴とする遺伝性疾患の診断評価に関連します。この検査の範囲と定義には、ヘモグロビン異常症を特定するための遺伝子スクリーニング、電気泳動、その他の高度な診断技術が含まれます。この検査は早期診断の促進、重症度の評価、治療方針の決定に必要です。その用途は出生前のスクリーニングから集団ベースの調査まで多岐にわたり、個別化されたケアの最適化と公衆衛生の成果の向上に役立っています。エンドユーザーには主に病院、診断研究所、調査機関が含まれます。市場の成長は、意識の高まりによるヘモグロビン異常症の有病率の上昇、遺伝子検査法の技術的進歩、新興市場における政府の取り組みに大きく影響されています。調査によると、AIと機械学習を診断プロセスに統合することで、精度の向上とコストの削減によって大きなビジネスチャンスがもたらされる一方、バイオテクノロジー企業と研究機関のコラボレーションによってイノベーションがさらに促進される可能性があります。しかし、同市場は、検査技術の高コスト、低リソース環境での限られたアクセス、熟練したヘルスケア専門家の必要性などの課題に直面しています。また、設備や運営にかかるコストが高いことも、小規模な検査施設にとっては採用の足かせとなります。技術革新と研究開発の機会は、費用対効果の高いハイスループット・スクリーニング法や携帯型診断薬を開発することにあります。さらに、CRISPRや遺伝子編集技術の進歩は、治療的解決策を提供する可能性があり、研究開発のもう一つの道を示しています。市場の性質は競争的でありながら協調的であるため、事業拡大と研究開発投資のための戦略的パートナーシップが必要となります。公開会社は、規制上のハードルを乗り越えるために公衆衛生機関と協力しながら、幅広いアクセシビリティとアフォーダビリティに焦点を当てるべきです。参入に成功した企業や既存企業は、技術的な適応による差別化を優先し、農村部や十分なサービスを受けていない人々のアンメットニーズに対応することで、効果的な市場獲得を目指すべきです。

市場力学：急速に進化する成人ヘモグロビン血症検査市場の主要市場インサイトを公開

成人ヘモグロビン血症検査市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界のサラセミアおよび鎌状赤血球症（SCD）の有病率
  • 疾患の早期診断と治療への傾向
  • 継続的な新生児スクリーニングプログラムと正確で信頼性の高い検査手法の必要性
• 市場抑制要因
  • 成人ヘモグロビン血症検査に伴う高コスト
• 市場機会
  • 成人ヘモグロビン症検査法の技術的進歩
  • 成人ヘモグロビン症に関する継続的な研究開発
• 市場の課題
  • 成人ヘモグロビン血症検査に使用される機器の技術的限界

ポーターのファイブフォース：成人ヘモグロビン血症検査市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：成人ヘモグロビン血症検査市場における外部からの影響の把握

外部マクロ環境要因は、成人ヘモグロビン血症検査市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析成人ヘモグロビン血症検査市場における競合情勢の把握

成人ヘモグロビン血症検査市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス成人ヘモグロビン血症検査市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、成人ヘモグロビン血症検査市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨成人ヘモグロビン血症検査市場における成功への道筋を描く

成人ヘモグロビン血症検査市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報に基づいた意思決定を行う上で役立つ重要な質問にも回答しています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中でのサラセミアと鎌状赤血球症（SCD）の有病率
    • 病気の早期診断と治療への傾向
    • 新生児スクリーニングプログラムの継続と正確で信頼性の高い検査方法の必要性
  • 抑制要因
    • 成人ヘモグロビン症検査に伴う高コスト
  • 機会
    • 成人ヘモグロビン症検査方法の技術的進歩
    • 成人ヘモグロビン症に関する継続的な研究開発
  • 課題
    • 成人ヘモグロビン症検査に使用される機器の技術的限界
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 成人ヘモグロビン血症検査市場グループ別

• 構造ヘモグロビン変異体
• サラセミア症候群

第7章 成人ヘモグロビン血症検査市場：タイプ別

• Hb電気泳動
• HPLC検出
• 質量分析

第8章 成人ヘモグロビン血症検査市場：最終用途別

• 病院
• 研究所
• 医療調査機関

第9章 南北アメリカの成人ヘモグロビン血症検査市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の成人ヘモグロビン血症検査市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの成人ヘモグロビン血症検査市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• ARKRAY, Inc.
• Beckman Coulter, Inc. by Danaher Corporation
• Bio-Rad Laboratories, Inc.
• Bluebird Bio, Inc.
• Creative Diagnostics
• F. Hoffmann-La Roche Ltd.
• HORIBA Group
• Illumina, Inc.
• Laboratory Corporation of America Holdings
• Merck KGaA
• PerkinElmer, Inc.
• Quest Diagnostics Incorporated
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• Shimadzu Corporation
• Siemens Healthineers AG
• Sysmex Europe SE
• Thermo Fisher Scientific Inc.
• Tosoh Corporation
• Trinity Biotech PLC

LIST OF FIGURES

• FIGURE 1. ADULT HEMOGLOBINOPATHY TESTING MARKET RESEARCH PROCESS
• FIGURE 2. ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ADULT HEMOGLOBINOPATHY TESTING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. ADULT HEMOGLOBINOPATHY TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ADULT HEMOGLOBINOPATHY TESTING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ADULT HEMOGLOBINOPATHY TESTING MARKET DYNAMICS
• TABLE 7. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY STRUCTURAL HEMOGLOBIN VARIANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY THALASSEMIA SYNDROMES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HB ELECTROPHORESIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HPLC DETECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY MEDICAL & RESEARCH INSTITUTE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 28. CANADA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 29. CANADA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 30. CANADA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 45. CHINA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 46. CHINA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 47. CHINA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 48. INDIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 49. INDIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. INDIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 100. ITALY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 101. ITALY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. ITALY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 112. POLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 113. POLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 114. POLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 115. QATAR ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 116. QATAR ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. QATAR ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 145. ADULT HEMOGLOBINOPATHY TESTING MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 146. ADULT HEMOGLOBINOPATHY TESTING MARKET, FPNV POSITIONING MATRIX, 2023

The Adult Hemoglobinopathy Testing Market was valued at USD 4.72 billion in 2023, expected to reach USD 5.10 billion in 2024, and is projected to grow at a CAGR of 6.17%, to USD 7.18 billion by 2030.

Adult hemoglobinopathy testing pertains to the diagnostic evaluation of inherited disorders characterized by abnormal hemoglobin production, such as sickle cell disease and beta-thalassemia, in adults. The scope and definition of this testing encompass genetic screenings, electrophoresis, and other advanced diagnostic techniques to identify hemoglobinopathies. This testing is necessary for promoting early diagnosis, assessing severity, and guiding treatment decisions. Its applications range from prenatal screenings to population-based studies, serving in optimizing individualized care and improving public health outcomes. End-users primarily include hospitals, diagnostic laboratories, and research institutions. The market's growth is significantly influenced by a rising prevalence of hemoglobinopathies due to increased awareness, technological advancements in genetic testing methods, and government initiatives in emerging markets. Insights reveal that integrating AI and machine learning in diagnostic processes presents substantial opportunities by enhancing accuracy and reducing costs, while collaborations between biotech firms and research organizations can further spur innovation. However, the market faces challenges like high costs of testing technologies, limited access in low-resource settings, and a need for skilled healthcare professionals. High equipment and operational costs can also deter smaller laboratories from adoption. Innovation and research opportunities lie in developing cost-effective, high-throughput screening methods and portable diagnostics that could democratize accessibility. Furthermore, advancements in CRISPR and gene-editing technologies could potentially offer therapeutic solutions, highlighting another avenue for research and development. The market's nature is competitive yet collaborative, necessitating strategic partnerships for expansion and R&D investment. Companies should focus on broad accessibility and affordability, collaborating with public health entities to navigate regulatory hurdles. Successful entrants and established firms should prioritize differentiation through technological adaptation, addressing the unmet needs in rural and underserved populations for effective market capture.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Adult Hemoglobinopathy Testing Market

The Adult Hemoglobinopathy Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Prevalence of thalassemia and sickle cell disease (SCD) worldwide
  • Inclination toward early diagnosis and treatment of diseases
  • Ongoing newborn screening programs and need for accurate and reliable testing methodologies
• Market Restraints
  • High cost associated with adult-hemoglobinopathy-testing
• Market Opportunities
  • Technological advancements in adult-hemoglobinopathy-testing methods
  • Ongoing research and development on adult-hemoglobinopathy
• Market Challenges
  • Technical limitations in devices used for adult-hemoglobinopathy-testing

Porter's Five Forces: A Strategic Tool for Navigating the Adult Hemoglobinopathy Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Adult Hemoglobinopathy Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Adult Hemoglobinopathy Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Adult Hemoglobinopathy Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Adult Hemoglobinopathy Testing Market

A detailed market share analysis in the Adult Hemoglobinopathy Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Adult Hemoglobinopathy Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Adult Hemoglobinopathy Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Adult Hemoglobinopathy Testing Market

A strategic analysis of the Adult Hemoglobinopathy Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Adult Hemoglobinopathy Testing Market, highlighting leading vendors and their innovative profiles. These include ARKRAY, Inc., Beckman Coulter, Inc. by Danaher Corporation, Bio-Rad Laboratories, Inc., Bluebird Bio, Inc., Creative Diagnostics, F. Hoffmann-La Roche Ltd., HORIBA Group, Illumina, Inc., Laboratory Corporation of America Holdings, Merck KGaA, PerkinElmer, Inc., Quest Diagnostics Incorporated, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Shimadzu Corporation, Siemens Healthineers AG, Sysmex Europe SE, Thermo Fisher Scientific Inc., Tosoh Corporation, and Trinity Biotech PLC.

Market Segmentation & Coverage

This research report categorizes the Adult Hemoglobinopathy Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Group, market is studied across Structural Hemoglobin Variants and Thalassemia Syndromes.
• Based on Type, market is studied across Hb Electrophoresis, HPLC Detection, and Mass Spectrometry.
• Based on End-Use, market is studied across Hospital, Laboratories, and Medical & Research Institute.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of thalassemia and sickle cell disease (SCD) worldwide
    • 5.1.1.2. Inclination toward early diagnosis and treatment of diseases
    • 5.1.1.3. Ongoing newborn screening programs and need for accurate and reliable testing methodologies
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with adult-hemoglobinopathy-testing
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements in adult-hemoglobinopathy-testing methods
    • 5.1.3.2. Ongoing research and development on adult-hemoglobinopathy
  • 5.1.4. Challenges
    • 5.1.4.1. Technical limitations in devices used for adult-hemoglobinopathy-testing
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Adult Hemoglobinopathy Testing Market, by Group

• 6.1. Introduction
• 6.2. Structural Hemoglobin Variants
• 6.3. Thalassemia Syndromes

7. Adult Hemoglobinopathy Testing Market, by Type

• 7.1. Introduction
• 7.2. Hb Electrophoresis
• 7.3. HPLC Detection
• 7.4. Mass Spectrometry

8. Adult Hemoglobinopathy Testing Market, by End-Use

• 8.1. Introduction
• 8.2. Hospital
• 8.3. Laboratories
• 8.4. Medical & Research Institute

9. Americas Adult Hemoglobinopathy Testing Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Adult Hemoglobinopathy Testing Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Adult Hemoglobinopathy Testing Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. ARKRAY, Inc.
• 2. Beckman Coulter, Inc. by Danaher Corporation
• 3. Bio-Rad Laboratories, Inc.
• 4. Bluebird Bio, Inc.
• 5. Creative Diagnostics
• 6. F. Hoffmann-La Roche Ltd.
• 7. HORIBA Group
• 8. Illumina, Inc.
• 9. Laboratory Corporation of America Holdings
• 10. Merck KGaA
• 11. PerkinElmer, Inc.
• 12. Quest Diagnostics Incorporated
• 13. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• 14. Shimadzu Corporation
• 15. Siemens Healthineers AG
• 16. Sysmex Europe SE
• 17. Thermo Fisher Scientific Inc.
• 18. Tosoh Corporation
• 19. Trinity Biotech PLC